PDF(Pubmed)
Abstract：
BACKGROUND: Sodium-glucose transporter-2 inhibitors (SGLT-2i) are recommended for use in patients with type 2 diabetes comorbid atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. Limited reports are currently available for their use in dialysis patients. In an observational, retrospective follow-up study, we reported the clinical characteristics of chronic peritoneal dialysis (PD) patients on SGLT-2i.
METHODS: We enrolled 50 diabetic chronic PD patients, and 11 continued SGLT-2i after PD treatment. We reported the patients\' ultrafiltration, HbA1c, urinary tract infection episodes, and venous CO2 during follow-up and compared the differences in these factors between patients with and without SGLT-2i.
RESULTS: The mean age of the patients was 65 ± 15 years, and 16 (32%) patients were female. The age, gender, heart failure, and primary kidney disease were not different between patients with and without SGLT-2i at enrollment. In an average of 31 months follow-up, patients with SGLT-2i had higher ultrafiltration (1322 ± 200 ml/day vs. 985 ± 415 ml/day, p = 0.013), hemoglobin (11.2 ± 1.7 vs. 10.2 ± 1.7 g/dl), white blood cell count (9.2 ± 3.7 vs. 7.4 ± 2.1 109/L), and a lower venous CO2 (p = 0.036). The urine amount, the overall survival, the technical survival, and the chance of UTI were not different between patients with and without SGLT2i.
CONCLUSIONS: SGLT-2i may increase ultrafiltration volume and hemoglobin levels in chronic PD patients. SGLT-2i did not increase urinary tract infection but was linked to subclinical metabolic acidosis.
UNASSIGNED: The effect of SGLT-2i in chronic PD patients is not clear?
UNASSIGNED: SGLT-2i is associated with increased ultrafiltration, hemoglobin, white blood cell counts, and a decreased CO2 in PD patient.
UNASSIGNED: SGLT-2i may increase ultrafiltration in PD patients.
METHODS: We enrolled 50 diabetic chronic PD patients, and 11 continued SGLT-2i after PD treatment. We reported the patients\' ultrafiltration, HbA1c, urinary tract infection episodes, and venous CO2 during follow-up and compared the differences in these factors between patients with and without SGLT-2i.
RESULTS: The mean age of the patients was 65 ± 15 years, and 16 (32%) patients were female. The age, gender, heart failure, and primary kidney disease were not different between patients with and without SGLT-2i at enrollment. In an average of 31 months follow-up, patients with SGLT-2i had higher ultrafiltration (1322 ± 200 ml/day vs. 985 ± 415 ml/day, p = 0.013), hemoglobin (11.2 ± 1.7 vs. 10.2 ± 1.7 g/dl), white blood cell count (9.2 ± 3.7 vs. 7.4 ± 2.1 109/L), and a lower venous CO2 (p = 0.036). The urine amount, the overall survival, the technical survival, and the chance of UTI were not different between patients with and without SGLT2i.
CONCLUSIONS: SGLT-2i may increase ultrafiltration volume and hemoglobin levels in chronic PD patients. SGLT-2i did not increase urinary tract infection but was linked to subclinical metabolic acidosis.
UNASSIGNED: The effect of SGLT-2i in chronic PD patients is not clear?
UNASSIGNED: SGLT-2i is associated with increased ultrafiltration, hemoglobin, white blood cell counts, and a decreased CO2 in PD patient.
UNASSIGNED: SGLT-2i may increase ultrafiltration in PD patients.
摘要：
背景：钠-葡萄糖转运蛋白-2抑制剂（SGLT-2i）被推荐用于患有动脉粥样硬化性心血管疾病的2型糖尿病患者，心力衰竭,或慢性肾病.目前可用于透析患者的报告有限。在观察中，回顾性随访研究,我们报告了SGLT-2i慢性腹膜透析（PD）患者的临床特征。
方法：我们招募了50名糖尿病慢性PD患者，11例PD治疗后继续SGLT-2i。我们报道了患者的超滤，HbA1c,尿路感染发作，和随访期间的静脉CO2，并比较了有和没有SGLT-2i的患者在这些因素方面的差异。
结果：患者的平均年龄为65±15岁，16例（32%）患者为女性。年龄,性别,心力衰竭,纳入时,有和无SGLT-2i的患者与原发性肾脏疾病无差异.在平均31个月的随访中，SGLT-2i患者的超滤量较高（1322±200ml/dayvs.985±415毫升/天，p=0.013),血红蛋白(11.2±1.7vs.10.2±1.7g/dl)，白细胞计数(9.2±3.7vs.7.4±2.1109/L),和较低的静脉CO2（p=0.036）。尿量,总生存率,技术生存，在有和没有SGLT2i的患者之间，UTI的机会没有差异。
结论：SGLT-2i可能增加慢性PD患者的超滤量和血红蛋白水平。SGLT-2i不会增加尿路感染，但与亚临床代谢性酸中毒有关。
■SGLT-2i在慢性PD患者中的作用尚不清楚？
■SGLT-2i与超滤增加有关，血红蛋白,白细胞计数,PD患者的二氧化碳减少。
■SGLT-2i可能会增加PD患者的超滤。
方法：我们招募了50名糖尿病慢性PD患者，11例PD治疗后继续SGLT-2i。我们报道了患者的超滤，HbA1c,尿路感染发作，和随访期间的静脉CO2，并比较了有和没有SGLT-2i的患者在这些因素方面的差异。
结果：患者的平均年龄为65±15岁，16例（32%）患者为女性。年龄,性别,心力衰竭,纳入时,有和无SGLT-2i的患者与原发性肾脏疾病无差异.在平均31个月的随访中，SGLT-2i患者的超滤量较高（1322±200ml/dayvs.985±415毫升/天，p=0.013),血红蛋白(11.2±1.7vs.10.2±1.7g/dl)，白细胞计数(9.2±3.7vs.7.4±2.1109/L),和较低的静脉CO2（p=0.036）。尿量,总生存率,技术生存，在有和没有SGLT2i的患者之间，UTI的机会没有差异。
结论：SGLT-2i可能增加慢性PD患者的超滤量和血红蛋白水平。SGLT-2i不会增加尿路感染，但与亚临床代谢性酸中毒有关。
■SGLT-2i在慢性PD患者中的作用尚不清楚？
■SGLT-2i与超滤增加有关，血红蛋白,白细胞计数,PD患者的二氧化碳减少。
■SGLT-2i可能会增加PD患者的超滤。
